Wednesday, July 8, 2026

Patent intelligence · US

US 9498432

Injectable flowable composition comprising buprenorphine

granted A61KA61K31/00A61K31/4748A61K31/485
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 10
Applicant portfolio 34
Patent details — US 9498432
Jurisdiction
US
Status
granted
Grant date
Nov 22, 2016
Expiration
Nov 17, 2036
Claims
16
CPC classes
A61K, A61K31/00, A61K31/4748, A61K31/485
View on Google Patents ↗

Quick answer

US 9498432 (Injectable flowable composition comprising buprenorphine) is held by Indivior UK Limited. Status: granted. Granted Nov 22, 2016. Expires Nov 17, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
16
CPC classes
A61K, A61K31/00, A61K31/4748, A61K31/485, A61K47/22, A61K47/34

More from Indivior UK Limited

Related pharmaceutical patents in our USPTO index.

  1. US 12290596

    Compositions and methods for the treatment of opioid overdose

    Indivior UK Limited · Expires May 1, 2045

    granted
  2. US 11839611

    Buprenorphine dosing regimens

    Indivior UK Limited · Expires Dec 7, 2043

    granted
  3. US 11712475

    Sustained delivery formulations of risperidone compound

    Indivior UK Limited · Expires Jul 27, 2043

    granted
  4. US 11135216

    Sublingual and buccal film compositions

    Indivior UK Limited · Expires Sep 30, 2041

    granted
  5. US 11110093

    Sustained release small molecule drug formulation

    Indivior UK Limited · Expires Sep 2, 2041

    granted
  6. US 11013809

    Sustained delivery formulations of risperidone compound

    Indivior UK Limited · Expires May 20, 2041

    granted
  7. US 11000520

    Buprenorphine dosing regimens

    Indivior UK Limited · Expires May 6, 2041

    granted
  8. US 10654842

    Dopamine D3 receptor antagonist compounds

    Indivior UK Limited · Expires May 14, 2040

    granted

Frequently asked questions

What is US patent 9498432?

US 9498432 (Injectable flowable composition comprising buprenorphine) is held by Indivior UK Limited. Status: granted. Granted Nov 22, 2016. Expires Nov 17, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 9498432?

Indivior UK Limited is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 34 pharmaceutical patents for this assignee.

When does US 9498432 expire?

Our index shows an expiration date of Nov 17, 2036 (10 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.